-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, for use in a method of treating and/or preventing a condition in an individual in need thereof, the method comprising administering to the individual a therapeutically effective amount of the Compound 1, or the pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein the condition is selected from the following: systemic scleroderma; diffuse systemic scleroderma; limited systemic scleroderma; systemic sclerosis; diffuse systemic sclerosis; limited systemic sclerosis; scleroderma; diffuse scleroderma; limited scleroderma; CREST syndrome; diffuse cutaneous systemic sclerosis; limited cutaneous systemic sclerosis; diffuse cutaneous scleroderma; limited cutaneous scleroderma; localized scleroderma; morphea; linear scleroderma; scleroderma en coup de sabre; sine scleroderma; progressive systemic sclerosis; progressive scleroderma; systemic sclerosis with associated interstitial lung disease; scleroderma with associated interstitial lung disease; systemic sclerosis with alveolitis; scleroderma with alveolitis; alveolitis associated with systemic sclerosis; alveolitis associated with scleroderma; systemic sclerosis with lung fibrosis; scleroderma with lung fibrosis; lung fibrosis associated with systemic sclerosis; lung fibrosis associated with scleroderma; systemic sclerosis with pulmonary fibrosis; scleroderma with pulmonary fibrosis; pulmonary fibrosis associated with systemic sclerosis; pulmonary fibrosis associated with scleroderma; renal crisis associated with systemic sclerosis; renal crisis associated with scleroderma; diffuse scleroderma with evidence of fibrosing alveolitis; and systemic sclerosis with diffuse cutaneous involvement. or a pharmaceutically acceptable salt, hydrate, or solvate thereof, for use in a method of treating and/or preventing a condition in an individual in need thereof, the method comprising administering to the individual a therapeutically effective amount of the Compound 1, or the pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein the condition is selected from the following: systemic scleroderma; diffuse systemic scleroderma; limited systemic scleroderma; systemic sclerosis; diffuse systemic sclerosis; limited systemic sclerosis; scleroderma; diffuse scleroderma; limited scleroderma; CREST syndrome; diffuse cutaneous systemic sclerosis; limited cutaneous systemic sclerosis; diffuse cutaneous scleroderma; limited cutaneous scleroderma; localized scleroderma; morphea; linear scleroderma; scleroderma en coup de sabre; sine scleroderma; progressive systemic sclerosis; progressive scleroderma; systemic sclerosis with associated interstitial lung disease; scleroderma with associated interstitial lung disease; systemic sclerosis with alveolitis; scleroderma with alveolitis; alveolitis associated with systemic sclerosis; alveolitis associated with scleroderma; systemic sclerosis with lung fibrosis; scleroderma with lung fibrosis; lung fibrosis associated with systemic sclerosis; lung fibrosis associated with scleroderma; systemic sclerosis with pulmonary fibrosis; scleroderma with pulmonary fibrosis; pulmonary fibrosis associated with systemic sclerosis; pulmonary fibrosis associated with scleroderma; renal crisis associated with systemic sclerosis; renal crisis associated with scleroderma; diffuse scleroderma with evidence of fibrosing alveolitis; and systemic sclerosis with diffuse cutaneous involvement. the method comprising administering to the individual a therapeutically effective amount of the Compound 1, or the pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein the condition is selected from the following: systemic scleroderma; diffuse systemic scleroderma; limited systemic scleroderma; systemic sclerosis; diffuse systemic sclerosis; limited systemic sclerosis; scleroderma; diffuse scleroderma; limited scleroderma; CREST syndrome; diffuse cutaneous systemic sclerosis; limited cutaneous systemic sclerosis; diffuse cutaneous scleroderma; limited cutaneous scleroderma; localized scleroderma; morphea; linear scleroderma; scleroderma en coup de sabre; sine scleroderma; progressive systemic sclerosis; progressive scleroderma; systemic sclerosis with associated interstitial lung disease; scleroderma with associated interstitial lung disease; systemic sclerosis with alveolitis; scleroderma with alveolitis; alveolitis associated with systemic sclerosis; alveolitis associated with scleroderma; systemic sclerosis with lung fibrosis; scleroderma with lung fibrosis; lung fibrosis associated with systemic sclerosis; lung fibrosis associated with scleroderma; systemic sclerosis with pulmonary fibrosis; scleroderma with pulmonary fibrosis; pulmonary fibrosis associated with systemic sclerosis; pulmonary fibrosis associated with scleroderma; renal crisis associated with systemic sclerosis; renal crisis associated with scleroderma; diffuse scleroderma with evidence of fibrosing alveolitis; and systemic sclerosis with diffuse cutaneous involvement.